- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Tech, healthcare slide weighs on rest of markets.
Healthcare's slide weighs on rest of markets.
The stock has been on fire.
If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.